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Introduction	  The	   immune	   system	  performs	   several	  difficult	   balancing	  acts	  when	   reacting	   to	  microbes.	   It	   is	   geared	   to	   eliminate	   pathogens	   and	   to	   tolerate	   non-­‐pathogenic	  microbiota;	   it	  must	  mount	   a	   response	   to	   infection,	   but	  modulate	   the	   intensity	  and	   duration	   of	   the	   attack	   to	   limit	   damage	   to	   the	   host.	   There	   are	   numerous	  examples	   which	   show	   the	   adverse	   consequences	   of	   imbalanced	   cytokine	  networks	  during	  infection:	  immunopathology	  when	  pro-­‐inflammatory	  cytokines	  are	   not	   controlled	   or	   regulatory	   cytokines	   are	   absent,	   and	   inefficient	   virus	  elimination	  leading	  to	  chronicity	  or	  pathogen-­‐induced	  death	  when	  the	  cytokine	  response	   is	   qualitatively	   aberrant	   or	   too	   weak.	   A	   multitude	   of	   stromal	   and	  immune	  cell	  types	  deliver	  and	  receive	  cytokine	  signals,	  and	  viruses	  have	  evolved	  to	  suppress	  or	  subvert	  cytokine	  induction	  or	  evade	  the	  consequences	  of	  cytokine	  action.	  While	  we	  are	  beginning	  to	  understand	  parts	  of	  these	  networks,	  there	  are	  certainly	   still	   more	   questions	   than	   answers,	   and	   the	   modulation	   of	   cytokine	  actions	   for	   therapeutic	   use	   in	   infection	   is	   still	   in	   its	   infancy.	  Here,	  we	  describe	  recent	  progress	  in	  the	  understanding	  of	  cytokines	  and	  chemokines	  contributing	  to	   damage	   and	   protection	   during	   viral	   infection	   and	   viral	   -­‐	   bacterial	   co-­‐infections.	  We	  structure	   this	  review	  roughly	   following	   the	   families	  of	  cytokines	  involved	   in	   different	   response	   types	   (cytokines	   involved	   in	   innate	   immune	  responses,	   "regulatory"	   cytokines,	   Th17-­‐,	   Th1-­‐,	   Th2-­‐associated	   cytokines).	   The	  importance	  of	  cytokines	  in	  antiviral	  protection	  is	  demonstrated	  by	  the	  fact	  that	  most	  (if	  not	  all)	  viruses	  show	  signs	  that	  they	  have	  evolved	  to	  block	  the	  action	  of	  key	   immune	   mediators.	   For	   example,	   Poxvirus	   genomes	   typically	   encode	  approximately	   200	   genes,	   about	   90	   of	   which	   are	   in	   the	   central	   genome	   and	  encode	  essential	  viral	  proteins.	  The	  genes	  that	  cluster	  at	  each	  end	  of	  the	  genome	  tend	  to	  be	  host	  species-­‐specific	  and	  show	  evidence	  of	  horizontal	  eukaryotic	  gene	  transfer,	   conferring	   an	   advantage	   to	   the	   virus	   in	   controlling	   host	   responses	   to	  infection	  [1,2].	  	  
	  
Cytokines	  involved	  in	  the	  innate	  immune	  response	  
	  
Type	  I	  and	  III	  interferons	  and	  viruses	  
	  Type	  I	   interferons	  (IFNs)	  are	  a	   family	  of	  secreted	  cytokines	  comprised	  of	  more	  than	   10	   distinct	   IFNalpha	   (α)	   genes,	   one	   IFNbeta	   (β)	   gene	   and	   several	   other	  family	   members,	   which	   all	   elicit	   distinct	   antiviral	   effects.	   IFNs	   were	   first	  described	  by	  Isaacs	  and	  Lindenmann	  as	  soluble	   factors	  released	  from	  influenza	  virus	  infected	  cells	  that	  expressed	  anti-­‐viral	  properties	  [3].	  These	  properties	  are	  mediated	   through	   a	   vast	   number	   of	   effector	   molecules	   that	   are	   induced	   by	  autocrine	  or	  paracrine	  binding	  of	  IFNβ/IFNα	  to	  the	  IFNαβ	  receptor	  (reviewed	  in	  [4,5]).	  In	  2003,	  three	  highly	  related	  cytokines	  were	  discovered	  independently	  by	  two	  research	  groups:	  IL-­‐28A,	  IL-­‐28B	  and	  IL-­‐29	  [6,7].	  They	  are	  also	  designated	  as	  IFN-­‐λ2,	  λ3,	   and	  λ1,	   respectively,	   or	   together	   as	   type	   III	   IFNs.	   These	  mediators	  (reviewed	  in	  [8])	  are	  part	  of	  a	  larger	  family	  of	  related	  cytokines	  called	  the	  IL-­‐10–IFN	  family,	  which	  additionally	  contains	  the	  IL-­‐10-­‐like	  cytokines	  (IL-­‐10,	  IL-­‐19,	  IL-­‐20,	   IL-­‐22,	   IL-­‐24,	   and	   IL-­‐26),	   the	   type	   I	   IFNs	   (in	  humans:	   thirteen	   IFNα	   species,	  IFNβ,	  IFNε,	  IFNκ,	  and	  IFNϖ),	  and	  the	  type	  II	  IFN,	  IFNγ.	  Type	  I	  and	  Type	  III	  IFNs	  signal	  through	  Stat1/Stat2,	  albeit	  downstream	  of	  distinct	  receptors	  (Reviewed	  in	  [8,9]).	  	  The	   range	   of	   effector	   mechanisms	   downstream	   of	   IFN	   signaling	   is	   wide	   and	  continues	   to	   grow	   (reviewed	   in	   [10]).	   Type	   I	   IFNs	   themselves	   also	   induce	   a	  positive	  feedback	  loop	  and	  trigger	  the	  expression	  of	  IFN-­‐inducing	  proteins	  such	  as	  RIG-­‐I,	  NF-­‐κB	  and	  STATs.	  Probably	  the	  best	  indication	  of	  the	  potent	  anti-­‐viral	  effects	  of	  type	  I	  IFNs	  is	  the	  fact	  that	  many	  viruses	  dedicate	  part	  of	  their	  limited	  genome	   to	   counteracting	   type	   I	   IFN	   induction	   and	   signaling	   [5].	   That	   IFNα	   in	  combination	   with	   antivirals	   is	   successfully	   used	   as	   a	   therapy	   for	   chronic	  hepatitis	   C	   virus	   (HCV)	   infection	   underlines	   the	   practical	   implications	   of	   the	  protective	  potential	  of	  IFNs	  [11].	  	  
As	  both	   IFNα	  and	  β	   exclusively	   signal	   through	   the	   IFNαβR,	   the	   requirement	  of	  type	   I	   IFNs	   in	   viral	   infection	   has	   been	   extensively	   tested	   in	   IFNαβR	   deficient	  mice.	   The	   original	   papers	   showed	   increased	   susceptibility	   to	   infection	   by	  vesicular	   stomatitis	   virus	   (VSV),	   Semliki	   Forest	   virus,	   vaccinia	   virus	   and	  lymphocytic	   choriomeningitis	   virus	   (LCMV)	   [12].	   Additional	   viruses	   such	   as	  Theiler's	   virus	   and	  murine	   cytomegalovirus	   (MCMV)	  were	   added	   to	   the	   list	   of	  viruses	   targeted	   by	   IFNαβ	   (reviewed	   in	   [13]).	   More	   recently,	   infection	   by	  chikungunya	   virus	   was	   shown	   to	   be	   controlled	   by	   IFNαβ in	   mice	   [14].	  Interestingly,	   the	   virus	   appears	   not	   to	   induce	   IFNαβ	   in	   immune	   cells,	   and	  protection	   in	   mice	   depends	   on	   IFNαβ	   signaling	   in	   host	   stromal	   cells,	   as	  determined	   in	   bone	   marrow	   chimeras.	   Similarly,	   in	   a	   study	   comparing	   IFNαβ	  induction	   by	   respiratory	   syncytial	   virus	   (RSV)	   and	   influenza	   virus,	   the	  respiratory	   epithelium	   was	   a	   major	   source	   of	   IFNαβ	   in	   either	   infection,	   but	  depletion	  of	  plasmacytoid	  dendritic	  cells	  (pDC)	  had	  a	  major	  effect	  on	  type	  I	  IFN	  production	  only	  in	  the	  case	  of	  influenza	  infection	  [15].	  	  To	  further	  illustrate	  the	  complexity	  of	  the	  picture	  with	  influenza	  virus	  infection,	  IFNαβR	  KO	  mice	  show	  systemic	  viral	  dissemination	  with	  little	  to	  no	  increase	  in	  host	  susceptibility	  after	  infection	  with	  low	  pathogenicity	  influenza	  virus	  strains	  [16-­‐18],	  while	   a	   slightly	   greater	   effect	   is	   found	  when	  H5N1	   viruses	  were	   used	  [19].	   Similarly,	   IFNβ	   -­‐deficient	   mice	   show	   a	   higher	   susceptibility	   to	   influenza	  infection	  [20].	  The	  reason	  for	  the	  relatively	  mild	  phenotype	  most	  likely	  lies	  in	  the	  redundancy	   of	   the	   IFN	   systems.	   More	   dramatic	   increases	   in	   susceptibility	   are	  observed	   in	  mice	   lacking	   also	   another	   IFN	   system,	   namely	   IFN-­‐λ	   (IL-­‐28)	   [21].	  Thus,	  STAT1	  KO	  mice	   in	  which	  signaling	  through	  either	   IFNαβ,	   IFNγ	   (IFN-­‐Type	  II)	   or	   IFN-­‐lambda	   (IFN-­‐Type	   III	   –	   including	   IL-­‐28	   and	   IL-­‐29)	   is	   altered	   show	  higher	  susceptibility	  [16,17],	  as	  do	  the	  IFNαβR/IL28R	  double	  deficient	  mice	  [21].	  This	  is	  especially	  so	  if	  they	  also	  express	  a	  functional	  Mx	  gene	  [22]	  which	  in	  mice	  appears	  to	  play	  a	  predominant	  protective	  role	  among	  the	  many	  genes	  induced	  by	  IFN.	   Another	   factor	   possibly	   explaining	   the	   apparent	   relatively	   minor	  contribution	  of	   IFNαβ	  may	  be	   the	  highly	  efficient	  shut-­‐off	  of	   IFN	   induction	  and	  signaling	   by	   influenza	   virus,	   underscored	   by	   findings	   showing	   that	   viruses	  
deficient	   in	   the	   IFN-­‐suppressing	   protein	   NS1	   show	   greater	   differences	   in	  virulence	  in	  IFN-­‐deficient	  as	  opposed	  to	  IFN-­‐sufficient	  systems	  [23].	  	  IFNαβ	   have	   not	   only	   antiviral	   but	   also	   immunomodulatory	   functions	   for	   the	  production	  of	  pro-­‐inflammatory	  cytokines.	  This	  may	  explain	  some	  of	  the	  results	  in	  human	  infection	  with	  the	  highly	  pathogenic	  1918	  ‘Spanish	  Flu’	  strain	  and	  the	  H5N1	  avian	  strains,	  where	  hypercytokinemia-­‐	  associated	  immunopathology	  [24]	  was	  proposed	  as	  one	  the	  factors	  contributing	  to	  high	  mortality	  (reviewed	  in	  [25-­‐27]).	  Studies	  of	  macaques	   infected	  with	  H5N1	  strains	  showed	  early	  and	  strong	  induction	  of	  IFNαβ	  and	  proinflammatory	  cytokines	  [28].	  This	  is	  in	  line	  with	  the	  notion	  that	  type	  I	  IFNs	  can	  induce	  secretion	  of	  cytokines	  such	  as	  TNFα,	  IL-­‐6	  and	  IFNγ	  and	  with	  in	  vitro	  data	  demonstrating	  that	  human	  macrophages	  secrete	  high	  levels	  of	  IFNβ	  within	  hours	  of	  H5N1	  infection	  in	  vitro	  [29,30],	  and	  would	  suggest	  that	   the	   pro-­‐inflammatory	   effects	   of	   IFNαβ	   may	   dominate	   over	   its	   antiviral	  action	   under	   some	   circumstances.	   In	   contrast,	   studies	   conducted	   on	   human	  bronchial	  epithelial	  cells	  suggest	  that	  type	  I	  IFN	  levels	  are	  lower	  in	  response	  to	  infection	   with	   highly	   pathogenic	   H5N1	   as	   compared	   to	   seasonal	   strains	   [31].	  Similarly,	   severe	   disease	   due	   to	   the	   highly	   pathogenic	   1918	   strain	   of	   H1N1	   in	  macaques	   is	   correlated	   with	   persisting	   low	   levels	   of	   type	   I	   IFNs	   [32].	   In	   this	  study,	   lower	   levels	   of	   IFNαβ	   induced	   by	   the	   1918	   strain	   are	   associated	   with	  higher	  levels	  of	  IL-­‐6	  and	  other	  pro-­‐inflammatory	  cytokines.	  A	  more	  recent	  study	  correlates	  susceptibility	  or	  resistance	  to	  the	  same	  H5N1	  virus	  in	  back	  crosses	  of	  different	  mouse	  strains	  and	  describes	  that	  susceptibility	  correlates	  directly	  with	  levels	   of	   pro-­‐inflammatory	   cytokines	   and	   inversely	   with	   IFNαβ	   levels	   [33].	  Therefore,	   reduced	   IFNαβ	   levels	  may	   explain	   reduced	  virus	   control,	   consistent	  with	  the	  established	  antiviral	  role	  of	  IFNαβ.	  	  An	   additional	   or	   alternative	   explanation	   has	   been	   suggested	   for	   how	   reduced	  IFNαβ	  levels	  may	  lead	  to	  reduced	  virus	  control.	  Recent	  results	  demonstrate	  that	  IFNαβ	   antagonizes	   inflammasome	   and	   IL-­‐1	   induction	   [34].	   Therefore,	   if	   highly	  pathogenic	   influenza	  strains	  are	  more	  efficient	   in	   suppressing	   IFNαβ,	   then	   this	  may	   also	   allow	   higher	   levels	   of	   inflammasome	   activity,	   higher	   production	   of	  
mature	   IL-­‐1	   and	   strong	   induction	   of	   pro-­‐inflammatory	   cytokines,	   which	   could	  lead	   to	   enhanced	   pathology.	   However,	   the	   inverse	   correlation	   between	   IFNαβ	  and	  a	  range	  of	  pro-­‐inflammatory	  cytokines	  has	  not	  always	  been	  reported	  to	  be	  the	  case.	  In	  addition	  to	  the	  examples	  cited	  above,	  a	  recent	  study	  of	  the	  cytokine	  response	   of	   human	   epithelial	   cells	   to	   highly	   pathogenic	   H7N7	   viruses	   showed	  that	   the	   induction	   of	   both	   IFNαβ	   and	   pro-­‐inflammatory	   cytokines	   was	  attenuated	  in	  response	  to	  H7N7	  [35].	  However,	  it	  is	  possible	  that	  different	  effects	  on	   different	   cells	   of	   the	   innate	   and	   adaptive	   immune	   response	   may	   result	   in	  differential	   production	   of	   Type	   I	   IFNs	   and	   proinflammatory	   cytokines,	   which	  together	  will	  contribute	  to	  either	  viral	  clearance	  and/or	  immunopathology.	  	  
IFNαβ 	  and	  co-­infection	  	  The	  immunmodulatory	  functions	  of	  IFNαβ	  will	  impact	  not	  only	  on	  the	  course	  of	  the	  primary	  viral	  infection,	  but	  also	  on	  subsequent	  infection.	  	  
Type	  I	  IFNs	  can	  promote	  bacterial	  infections	  	  It	   has	   become	   clear	   in	   recent	   years	   that	   the	   majority	   of	   patients	   dying	   with	  influenza	  develop	  severe	  bacterial	  pneumonia,	  and	  the	  reasons	  for	  the	  increased	  susceptibility	   to	   co-­‐infection	   are	   under	   intense	   study	   [36].	   The	   production	   of	  type	   I	   IFN	   is	   associated	   with	   suppression	   of	   the	   innate	   response	   to	   bacterial	  infections.	   Indeed,	   indications	   that	   IFNαβ	   may	   interfere	   with	   antibacterial	  responses	  came	  from	  Listeria	  models	  where	  IFNαβ	  deficient	  mice	  were	  shown	  to	  be	  more	  resistant	  to	  infection	  [37-­‐39].	  The	  same	  observation	  was	  made	  recently	  in	   infection	  with	   the	   parasite	  Trypanosoma	   cruzi	   [40].	   Similarly,	   infection	  with	  
Mycobacterium	  tuberculosis	  is	  more	  severe	  when	  mice	  are	  pre-­‐treated	  with	  poly	  I:C,	   and	   this	   effect	   has	   been	   shown	   to	   be	   IFNαβ-­‐mediated	   [41].	   Several	  mechanisms	  have	  been	  put	  forward	  to	  explain	  this	  phenomenon,	  one	  of	  which	  is	  the	   inhibition	   of	   inflammasome	   activation	   and	   IL-­‐1	   production,	   as	   mentioned	  above	   [34].	   In	   this	   study,	   poly	   I:C-­‐induced	   IFNαβ	   was	   shown	   to	   reduce	   IL-­‐1β	  production	   which	   renders	   subsequent	   Candida	   infection	   more	   efficient	   [34].	  
Other	   explanations	   include	   the	   interference	   of	   IFNαβ	   with	   IFNγ	   signalling	   in	  Listeria	   infection	   [42],	   the	   suppression	  of	  Th17	   induction	  by	   IFNαβ-­‐dependent	  inhibition	   of	   osteopontin,	   which	   leads	   to	   de-­‐repression	   of	   the	   regulatory	  cytokine	  IL27	  in	  DCs	  and	  reduced	  and	  delayed	  Th17	  responses	  [43],	  or	  reduction	  of	   the	   neutrophil	   chemoattractants	   KC	   and	   MIP-­‐2,	   leading	   to	   decreased	  neutrophil	   influx	   for	  antibacterial	  action	  [44].	   	  Seo	  et	  al	   [45]	  propose	  a	  cellular	  explanation	   for	   the	   differential	   induction	   of	   neutrophil	   chemoattractants	   in	  IFNαβR-­‐deficient	   mice	   upon	   influenza	   infection.	   In	   these	   mice,	   a	   different	  monocyte	   subset	   expressing	   intermediate	   levels	   of	   Ly6C	   was	   seen	   to	   be	  promoted	   in	   contrast	   to	   observations	   in	   wild	   type	   animals.	   These	   Ly6C	  intermediate	   monocytes	   produced	   more	   KC	   and	   Mip-­‐2	   leading	   to	   neutrophil	  influx	   in	  contrast	   to	   the	  Ly6C	  high	  monocytes	   induced	   in	  wild	  type	  mice	  which	  were	   strong	   producers	   of	   the	   monocyte	   chemoattractant	   MCP-­‐1	   (CCL2).	   In	  MCMV	   infection,	   IFNαβ	   was	   shown	   to	   be	   responsible	   for	   CCL-­‐2,	   -­‐7	   and	   -­‐12	  induction	   in	   the	   bone	   marrow,	   which	   serve	   as	   release	   factors	   for	   Ly6Chi	  inflammatory	  monocytes	  [46],	  which	  may	  explain	  the	  reduction	  of	  this	  monocyte	  subset	  in	  IFNαβR-­‐deficient	  mice.	  	  
Viral	   suppression	   of	   IFNαβ 	   can	   promote	   infection	   with	   opportunistic	  
viruses.	  	  In	  contrast	  to	  the	  described	  effects	  of	  IFNαβ	  promoting	  bacterial	  superinfection,	  certain	   viruses	   can	   suppress	   the	   production	   of	   Type	   I	   IFNs	   and	   render	   mice	  susceptible	  to	  superinfection	  with	  opportunistic	  viruses.	  For	  example,	  LCMV	  has	  been	  shown	  to	  facilitate	  viral	  superinfection	  by	   impairing	  IFNαβ	  production	  by	  pDCs	  and	  consequently	  decreasing	  NK	  cell	  activation	  leading	  to	  reduced	  control	  and	   increased	   early	   spread	   of	   MCMV	   used	   as	   a	   model	   for	   an	   opportunistic	  pathogen	   [47].	   This	   report	   is	   in	   line	  with	  previous	   in	   vitro	   findings	   of	   efficient	  suppression	   of	   IFNαβ	   production	   in	   human	   pDCs	   by	   measles	   virus	   and	   some	  strains	   of	   RSV,	   viruses	   associated	   with	   opportunistic	   infections	   and	   pathology	  [48,49].	   In	  conclusion,	   the	   immunomodulatory	  roles	  of	   IFNαβs	  appear	   to	  be	  as	  
complex	  as	  their	  antiviral	  roles,	  and	  the	  impact	  of	  IFNαβ	  in	  viral,	  bacterial	  and	  in	  co-­‐infections	  will	  keep	  researchers	  busy	  for	  years	  to	  come.	  	  
TNF,	  IL-­6,	  IL-­1	  and	  inflammasomes	  in	  virus	  infection	  	  As	  mentioned	  above,	  infection	  with	  highly	  pathogenic	  influenza	  strains	  is	  linked	  to	   hypercytokinemia	   [24],	   even	   though	   the	   causal	   relationship	   between	  pathogenicity	  and	  cytokines	   is	  still	  unclear.	  Studies	   in	  mice	  have	  confirmed	  the	  strong	  cytokine	  induction	  by	  highly	  pathogenic	  strains	  [27],	  but	  contributions	  of	  individual	   cytokines	   to	   disease	   severity	   have	   been	   difficult	   to	   pin	   down	   in	  cytokine-­‐deficient	  mice.	  When	  mice	  deficient	  for	  IL-­‐6,	  one	  of	  the	  most	  highly	  up-­‐regulated	   cytokines	   in	   infection	   with	   pathogenic	   influenza,	   were	   analyzed,	   no	  changes	   in	   susceptibility	   were	   found	   [50].	   These	   results	   confirm	   older	   data	  obtained	   with	   low	   pathogenicity-­‐strains	   [51].	   In	   contrast,	   TNFR1	   KO	   mice	  showed	  a	  slight	  delay	  in	  weight	  loss	  in	  response	  to	  high	  pathogenicity	  influenza	  infection	  [50],	  suggesting	  a	  minor	  contribution	  of	  TNFα	  to	  pathology,	  whereas	  in	  other	   studies	   of	   influenza	   and	   RSV	   infection,	   inhibition	   of	   TNF	   reduced	   the	  severity	   of	   virus-­‐specific	   lung	   immunopathology,	   inhibited	   T	   cell	   recruitment	  and	  attenuated	  viral	  clearance	  [52,53].	  	  Early	  publications	  show	  higher	  mortality	  of	  mice	  deficient	  in	  IL-­‐1R1	  or	  IL-­‐1β	   in	  response	   to	   influenza	   infection	   [54,55].	   This	   was	   confirmed	   by	   more	   recent	  results	   obtained	   with	   high	   pathogenicity	   influenza	   virus	   strains	   [50].	   These	  results	   suggest	   that	   although	   IL-­‐1	   may	   contribute	   to	   lung	   pathology	   it	  simultaneously	  contributes	  to	  virus	  clearance	  and	  resistance	  [27].	  Three	  studies	  have	  attempted	  to	  assess	  the	  requirements	  of	  inflammasome	  components	  for	  the	  immune	   response	   to	   influenza	   (reviewed	   in	   [56]).	   As	   inflammasomes	   are	  thought	  to	  be	  sensors	  of	  the	  integrity	  of	  cellular	  membranes,	  it	  may	  not	  come	  as	  a	  surprise	   that	  expression	  of	   the	   influenza	  proton	  channel	  M2	  by	   infected	  cells	  strongly	   induces	   inflammasomes	  [57].	  One	  of	   the	  three	  mentioned	  studies	  uses	  the	  potent	  inflammasome	  inducer	  alum	  to	  apply	  the	  virus	  intranasally	  [58].	  The	  other	   two	  studies	  both	   show	   that	  mice	  deficient	   in	   inflammasome	  components	  have	  increased	  mortality	  relatively	  late	  in	  influenza	  infection,	  and	  reach	  slightly	  
divergent	   conclusions	   [59,60].	   Thomas	   et	   al	   associated	   higher	   susceptibility	   to	  influenza	  of	  Nlrp3-­‐	  (=Nalp3-­‐)	  and	  caspase1-­‐deficient	  mice	  with	  lower	  neutrophil	  and	  macrophage	  influx	  [59].	  Ichinoe	  and	  colleagues,	  in	  contrast,	  reported	  higher	  susceptibility	   in	   mice	   deficient	   in	   apoptosis-­‐associated	   speck-­‐like	   protein	  containing	  a	  caspase	  recruitment	  domain	  (ASC)	  and	  in	  caspase	  1-­‐deficient	  mice,	  but	  not	   in	  Nalp3	  deficient	  mice,	  and	  concentrated	   their	   study	  on	  effects	  on	   the	  induction	   of	   the	   adaptive	   response	   [60].	   Major	   methodological	   differences	  between	  the	   latter	   two	  studies	   include	  different	  Nalp-­‐3	  deficient	  mouse	  strains	  used,	   and	   use	   of	   a	   lower	   infectious	   viral	   dose	   in	   the	   study	   of	   Ichinoe	   et	   al.	  Together,	  these	  data	  suggest	  a	  contribution	  of	  the	  inflammasome	  and	  of	  IL-­‐1β	  in	  protection	   against	   influenza,	   and	   further	   studies	   are	   awaited	   to	   understand	  which	  mechanisms	  are	  at	  work.	  However,	  IL-­‐1	  induction	  does	  not	  always	  equate	  with	   inflammasome	   action.	   An	   interesting	   study	   of	   adenovirus-­‐associated	  inflammation	  shows	  that	  this	  is	  mediated	  by	  IL-­‐1α	  rather	  than	  IL-­‐1β,	  and	  that	  IL-­‐1α	   processing	   for	  maturation	   is	   inflammasome-­‐independent	   but	   dependent	   on	  beta	   3	   integrin	   [61].	   It	   is	   important	   to	   understand	   the	   details	   of	   adenovirus-­‐induced	   inflammation	   as	   this	   represents	   one	   of	   the	   main	   complications	   of	  prophylactic	  or	  therapeutic	  approaches	  using	  adenovirus	  vectors.	  	  
Chemokines	  and	  anti-­viral	  responses	  
	  
CCR2-­	  and	  CCR5	  dependent	  chemokines	  Viruses	  have	  evolved	  numerous	  strategies	  to	  evade	  innate	  and	  acquired	  immune	  responses	  that	  may	  eliminate	  them	  in	  the	  infected	  host.	  Large	  DNA	  viruses,	  such	  as	  herpesviruses	  and	  poxviruses,	  encode	  homologues	  of	  chemokine	  ligands	  and	  chemokine	   receptors,	   and	   secreted	   chemokine	   binding	   proteins	   (CKBPs)	   to	  modulate	  chemokine	  activity	   (reviewed	   in	   [62])	  demonstrating	   the	   importance	  of	  chemokines	  in	  protection	  against	  viral	  infection.	  	  Most	   chemokines	   bind	   to	   more	   than	   one	   receptor,	   and	   most	   chemokine	  receptors	   recognize	   more	   than	   one	   ligand,	   making	   analysis	   of	   this	   complex	  network	   by	   the	   use	   of	   single-­‐gene	   targeted	   mice	   difficult.	   In	   the	   case	   of	   the	  monocyte	   and	  T	   cell	   chemokines	  Mip-­‐1α	   	   (CCL3),	  Mip-­‐1β	   (CCL4)	   and	  RANTES	  
(CCL5)	   which	   all	   bind	   to	   CCR5,	   some	   clarity	   has	   been	   achieved.	   The	   original	  report	   on	   Mip-­‐1α	   deficient	   mice	   showed	   that	   Coxsackievirus-­‐induced	  myocarditis	  and	  influenza-­‐induced	  pulmonitis	  were	  reduced	  [63],	  while	  little	  or	  no	  contribution	  of	  Mip-­‐1α	   to	  susceptibility	   to	  high	  pathogenicity	   influenza	  was	  found	   in	   later	   studies	   [50].	   CCR5	   KO	  mice	  were	  more	   susceptible	   to	   influenza	  infection	  showing	  higher	  mortality,	  increased	  monocyte	  recruitment	  to	  the	  lung	  and	   enhanced	   pulmonary	   pathology	   [64].	   Subsequent	   studies	   confirmed	   the	  increased	   susceptibility	   with	   another	   influenza	   virus	   strain	   and	   with	   Sendai	  virus	  [65].	  The	   finding	  that	  RANTES	  deficient	  mice	  closely	  resembled	  the	  CCR5	  phenotype	   [65]	   suggests	   that	   RANTES,	   not	   Mip-­‐1α	   is	   the	   predominant	   CCR5	  ligand	  in	  action	  in	  respiratory	  viral	  infection.	  The	  main	  effect	  observed	  in	  CCR5	  and	   RANTES	   deficient	   mice	   was	   not	   a	   lack	   in	   cell	   recruitment,	   but	   increased	  macrophage	   apoptosis,	   suggesting	   that	   CCR5	   promotes	   macrophage	   survival	  which,	   in	   turn	   helps	   clear	   the	   virus.	   RSV	   infection	   of	   epithelial	   cells	   and	  macrophages	  results	   in	  production	  of	  RANTES	  by	  resident	  cells	  during	  the	  first	  48	  h	  of	   infection	  leading	  to	  recruitment	  of	  CD4+	  and	  CD8+	  T	  cells	  and	  plays	  an	  important	  role	  in	  controlling	  viral	  replication	  [66].	  Later,	  RANTES	  from	  resident	  cells	  disappears,	  to	  be	  replaced	  by	  virally	  induced	  RANTES	  from	  recruited	  T	  cells.	  Blocking	  RANTES	  with	  Met-­‐RANTES	  at	  this	  time	  reduces	  immunopathology	  but	  does	   not	   influence	   the	   Th1/Th2	   balance.	   This	   study	   suggested	   that	   RANTES	  plays	  a	  central	  role	  in	  driving	  inflammation	  in	  RSV	  lung	  disease	  and	  that	  blocking	  its	   effect	   may	   prove	   beneficial	   in	   bronchiolitis.	   However,	   chemokine	   blockade	  might	  be	  beneficial	  in	  primary	  exposure	  but	  paradoxically	  may	  enhance	  disease	  during	  reinfection	  with	  the	  same	  pathogen	  reflecting	  different	  effects	  at	  different	  stages	  of	   infection	   [66].	  Mip-­‐1α	   is	   also	  produced	  biphasically	   in	  both	   the	   early	  (day	  1)	  and	  late	  (day	  6–7)	  stages	  of	  RSV	  infection.	  Mip-­‐1α	  depletion	  reduces	  the	  recruitment	  of	  T	  cells	  after	  RSV	  infection,	  increasing	  weight	  loss	  and	  illness	  [53].	  	  In	   contrast	   to	   the	   CCR5-­‐deficient	   mice	   showing	   higher	   monocyte	   influx,	   mice	  deficient	   in	  CCR2	   show	   less	  monocyte	   recruitment	   and	   less	   lung	  damage	  upon	  influenza	   infection	   than	   wild	   type	   mice	   [64].	   These	   findings	   were	   confirmed	  more	  recently	  and	  corroborated	  by	  the	  inverse	  experiment	  of	  overexpression	  of	  the	   CCR2	   ligand	   CCL2	   (MCP-­‐1)	   in	   the	   lung,	   which	   led	   to	   increased	   monocyte	  
influx,	   damage	   and	   mortality	   after	   high-­‐dose	   influenza	   infection	   [67].	   Further	  support	  for	  protection	  against	  influenza	  through	  reduced	  CCL2	  action	  came	  from	  the	   same	   group	   using	   a	   CCL2	   antagonist,	   which	   reduced	   mortality	   and	   lung	  pathology	  in	  infected	  mice.	  However,	  studies	  using	  less	  virulent	  strains	  or	  lower	  doses	   of	   influenza	   virus	   find	   contrasting	   results:	   CCL2-­‐deficient	   mice	   showed	  higher	   morbidity	   and	   higher	   virus	   titers	   after	   low-­‐dose	   infection	   [68],	   and	  neutralization	   of	   CCL2	   by	   mAb	   treatment	   led	   to	   increased	   lung	   damage	   and	  delayed	  tissue	  repair	  [69].	  These	  conflicting	  data	  were	  somewhat	  reconciled	  by	  a	  recent	   study	   showing	   complete	   absence	   of	   recruitment	   of	   CD11bhiLy6Chi	  monocytes	   after	   low	   dose	   infection	   of	   CCR2-­‐deficient	   mice	   [70].	   Since	   these	  monocytes	  or	  the	  cells	  they	  differentiate	  into	  can	  present	  antigen	  to	  CD8	  T	  cells,	  the	   influenza	  specific	  CD8	  T	  cell	   response	   is	  diminished.	  Pharmacological	  CCL2	  block	   reduced,	   but	   did	   not	   abolish	   monocyte	   recruitment,	   thereby	   improving	  disease	  outcome	  [70].	  Hence,	  massive	  recruitment	  of	  these	  cells	  after	  high-­‐dose	  infection	  may	  lead	  to	  severe	  immunopathology,	  while	  in	  low	  dose	  or	  less	  virulent	  infection,	   less	  monocytes	   are	   recruited	   leading	   to	   optimal	   CD8	   T	   cell	   priming.	  	  Since	  it	  was	  demonstrated	  in	  bacterial	  infection	  that	  the	  CCL2-­‐CCR2	  interaction	  mainly	   regulates	  monocyte	   egress	   from	   the	   bone	  marrow	  which	   subsequently	  allows	  stronger	  recruitment	  into	  infected	  sites	  [71],	  it	  is	  conceivable	  that	  during	  virus	  infection,	  the	  same	  mechanism	  is	  at	  work.	  In	  fact,	  a	  recent	  study	  shows	  the	  requirement	   of	   CCR2	   for	   bone	  marrow	   release	   of	  monocytes	   in	   infection	  with	  MCMV	   [46].	   Interestingly,	   the	   production	   of	   CCR2	   ligands	   by	   bone	   marrow-­‐resident	   leukocytes	   is	   dependent	   on	   IFNαβ	   which	   is	   induced	   during	   MCMV	  infection.	   Since	  macrophages	   are	   essential	   for	   local	  MCMV	   control	   in	   the	   liver,	  CCR2	  and	  CCL2	  deficient	  mice	  die	  rapidly	  from	  infection	  with	  this	  virus	  [72].	  	  
IL-­10	  and	  TGFβ 	  and	  immune	  evasion	  by	  viruses	  	  IL-­‐10	  is	  a	  cytokine	  with	  broad	  anti-­‐inflammatory	  properties	  by	  its	  suppression	  of	  both	  macrophage	   and	   dendritic	   cell	   function,	   including	   antigen	   presenting	   cell	  function	   and	   the	   production	   of	   proinflammatory	   cytokines	   [73,74],	   and	   more	  recently	  by	  direct	   effects	   on	  T	   cells	   [75-­‐77]	   that	   keep	  Th17	   cells	   in	   check.	  The	  presence	  of	  closely	  related	  homologues	  of	  IL-­‐10	  in	  several	  virus	  genomes	  further	  
supports	  its	  critical	  role	  in	  regulating	  immune	  and	  inflammatory	  responses	  [73].	  The	  fact	  that	  at	  least	  three	  viral	  lineages	  have	  independently	  captured	  host	  IL-­10	  genes	  supports	   the	  hypothesis	   that	  possession	  of	  an	   IL-­‐10	  molecule	  confers	  an	  advantage	   to	   a	   DNA	   virus	   infecting	   a	   mammal,	   presumably	   because	   of	   its	  disruptive	   effect	   on	   host	   immune	   system	   signaling	   [73,78].	   Several	  herpesviruses	   and	   poxviruses	   encode	   proteins	   related	   to	   the	   IL-­‐10	   family.	  Human	  herpesvirus	  4	   (Epstein–Barr	   virus)	   and	  Orf	   virus	   express	  proteins	   that	  are	   closely	   related	   to	   IL-­‐10	   from	   their	  human	  or	  ovine	  host,	   and	  viral	  proteins	  that	   are	   more	   distantly	   related	   to	   IL-­‐10	   are	   encoded	   by	   human	   and	   primate	  cytomegalovirus	  [73,79].	  Although	  the	  absence	  of	  IL-­‐10	  leads	  to	  better	  clearance	  of	  some	  pathogens	  with	  no	  enhanced	  immunopathology,	  during	  other	  infections	  the	   absence	   of	   IL-­‐10	   can	   be	   accompanied	   by	   immunopathology	   that	   is	  detrimental	   to	   the	   host,	   but	   does	   not	   necessarily	   affect	   the	   pathogen	   load	  (reviewed	   in	   [74]).	   IL-­‐10	  has	   important	   roles	   in	   limiting	   immune	   responses	   to	  viruses	  but,	  perhaps	  not	  surprisingly,	  with	  different	  outcomes,	  depending	  on	  the	  virus.	  Brooks	  et	  al	  [80]	  showed	  that	  compared	  to	  acute	  LCMV	  infection,	  chronic	  infection	   induced	   by	   an	   LCMV	   strain	   differing	   from	   the	   parental	   strain	   in	   only	  one	  amino	  acid	  is	  associated	  with	  an	  increase	  in	  IL-­‐10	  produced	  by	  conventional	  dendritic	  cells	  at	  day	  5	  post	  infection.	  When	  using	  the	  same	  LCMV	  strain	  in	  IL-­‐10	  deficient	  mice,	   the	  virus	  was	  cleared	  rapidly	   in	  an	  acute,	   self-­‐limiting	   infection,	  suggesting	   that	   this	   virus	  preferentially	   induced	   IL-­‐10	   to	   evade	   the	   innate	   and	  adaptive	   immune	   response.	   Similar	   results	   were	   reported	   simultaneously	   by	  another	   group	  who	   also	   showed	   that	  mAb-­‐mediated	   IL-­‐10	  blockage	   in	   chronic	  LCMV	   infection	   resulted	   in	   virus	   control	   [81].	   In	   persistent	  MCMV	   infection,	   it	  was	  shown	  that	  IL-­‐10	  producing	  CD4	  T	  cells	  accumulate	  in	  the	  preferential	  site	  of	   viral	   replication,	   the	   salivary	   gland,	   and	   that	   IL-­‐10	   blocking	   Abs	   lead	   to	  increased	   frequencies	   of	   IFNγ-­‐producing	  CD4	  T	   cells	   and	   reduced	  MCMV	   titers	  specifically	   in	   this	   organ	   [82],	   similarly	   to	  what	   has	   been	   discussed	   above	   for	  LCMV.	  Increased	  IL-­‐10	  has	  been	  linked	  to	  other	  chronic	  viral	   infections	  such	  as	  Mouse	  Mammary	  Tumour	  Virus	  (MMTV)	  and	  HCV	  (reviewed	  in	  [83,84]).	  Recent	  data	  from	  LCMV	  infection	  shows	  that	  IL-­‐10	  production	  is	  biphasic,	  with	  an	  initial	  peak	  at	  2d	  that	  is	  similar	  for	  acute	  and	  chronic	  infection.	  Therefore,	  even	  in	  acute	  
LCMV	   infection,	   blockade	   or	   absence	   of	   IL-­‐10	   increases	   the	   CD4	   response	   and	  enhances	  protection	  against	  the	  virus	  [85].	  	  	  More	  divergent	  effects	  of	  IL-­‐10	  were	  found	  in	  studies	  of	  another	  acute	  infection,	  namely	   influenza.	   Three	   groups	   have	   investigated	   infection	   of	   mice	   in	   the	  absence	  of	   IL-­‐10	  signalling	  and	  report	  contrasting	  results	  which	  may	  be	  due	  to	  differences	   in	   viral	   doses,	   genetic	   background	   of	   the	  mice,	   or	   the	  way	   IL-­‐10	   is	  neutralized	   [86-­‐88].	   Two	   publications	   showed	   that	   IL-­‐10	   promotes	   morbidity	  and	  mortality,	  in	  particular	  when	  virus	  doses	  are	  used	  that	  induce	  severe	  disease	  [86,87].	  In	  these	  studies,	  both	  IL-­‐10-­‐deficient	  mice	  on	  the	  BALB/c	  background	  or	  IL-­‐10	  neutralization	  by	  mAb	   injection	  one	  day	  before	   infection	  were	  employed	  and	   demonstrated	   better	   protection	   than	   controls.	   In	   one	   of	   the	   studies,	   IL-­‐10	  did	  not	  impact	  sublethal	  infection,	  heterosubtypic	  immunity,	  or	  the	  maintenance	  of	   long-­‐lived	   influenza	   Ag	   depots	   [87]	   but	   IL-­‐10-­‐deficient	   mice	   displayed	  dramatically	   increased	   survival	   as	   compared	   with	   wild-­‐type	   mice	   when	  challenged	   with	   lethal	   doses	   of	   virus.	   This	   increased	   survival	   correlated	   with	  increased	   expression	   of	   several	   Th17-­‐associated	   cytokines,	   including	   IL-­‐22,	   in	  the	   lungs	   of	   IL-­‐10-­‐deficient	   mice	   during	   the	   peak	   of	   infection,	   but	   not	   with	  unchecked	   inflammation	   or	   with	   increased	   cellular	   responses,	   nor	   effects	   on	  viral	   load	   and	  was	   independent	   of	   IFNγ	   production,	   perforin	   and	   IL-­‐17A	   [87].	  The	  second	  study	  showed	  that	  IL-­‐10	  deficient	  mice	  had	  improved	  viral	  clearance	  and	  survival	  after	  infection	  as	  compared	  to	  wild-­‐type	  mice.	  However,	  enhanced	  viral	  clearance	  in	  IL-­‐10	  deficient	  mice	  was	  not	  correlated	  with	  increased	  CD4+	  or	  CD8+	   T-­‐cell	   recruitment	   into	   the	   lung	   but	   was	   correlated	   with	   increased	  pulmonary	  anti-­‐influenza	  virus	  antibody	  titers,	  and	  this	  was	  dependent	  upon	  the	  presence	   of	   T	   cells,	   primarily	   CD4	   T	   cells.	   In	   addition,	   virus-­‐specific	   antibody	  produced	   during	   the	   early	   stages	   of	   infection	   in	   the	   respiratory	   tract	   of	   IL-­‐10	  deficient	   but	   not	   wild-­‐type	   mice	   was	   sufficient	   to	   mediate	   passive	   protection	  against	   viral	   challenge	   of	   naïve	  mice	   [86].	   In	   a	   third	   study,	   an	   influenza	   virus	  dose	   that	   induced	   low	  mortality	   in	   wild	   type	  mice	  was	   used,	   and	   in	   this	   case	  showed	   that	   IL-­‐10	   receptor	   blockade,	   from	   day	   3	   post	   influenza	   infection	  onwards,	  led	  to	  aggravated	  disease,	  but	  did	  not	  alter	  the	  titre	  of	  infectious	  virus	  in	  the	  lungs	  or	  virus	  clearance	  [88].	  In	  this	  case,	  the	  effect	  of	  IL-­‐10	  neutralization	  
at	   a	   later	   stage	   post	   infection	   may	   allow	   the	   virus	   to	   replicate	   to	   high	   titers,	  which	  subsequently	  may	  lead	  to	  an	  "over-­‐exuberant"	  immune	  response	  once	  IL-­‐10-­‐mediated	   regulation	   is	   removed	   by	   IL-­‐10R	   mAb	   neutralization.	   Whether	  these	  or	  other	  parameters	  tip	  the	  balance	  between	  efficient	  virus	  clearance	  and	  immune-­‐mediated	   pathology,	   collectively	   these	   results	   show	   that	   the	   cytokine	  balance	   is	   finely	   tuned,	   suggesting	   that	   intervention	  should	  be	  considered	  with	  caution	   in	   acute	   viral	   infections,	   such	   as	   influenza.	   Interestingly,	   CD8+	   T	   and	  CD4+	  cells	  are	  the	  main	  source	  of	  IL-­‐10	  identified	  in	  these	  studies,	  while	  little	  IL-­‐10	  is	  produced	  CD3-­‐negative	  cells	  [88].	  In	  a	  recent	  follow	  up	  [89],	  it	  was	  shown	  that	  CD8+	  T	  cells	  need	  IL-­‐2	  from	  CD4+	  T	  cells	  for	  IL-­‐10	  production,	  and	  that	  IL-­‐27	  from	  an	  innate	  source	  and	  Blimp-­‐1	  on	  CD8	  cells	  are	  also	  required.	  	  While	  the	  above	  studies	  concentrate	  on	  IL-­‐10	  produced	  by	  T	  cells,	  many	  innate	  immune	  cells	  can	  produce	  this	  cytokine	  as	  well.	  Monocytes	  and	  macrophages	  are	  known	  to	  be	  able	  to	  secrete	  IL-­‐10	  [74],	  and	  recently,	  neutrophils	  were	  added	  to	  the	  growing	  list	  of	  IL-­‐10	  producers	  [90].	  In	  influenza	  infection,	  it	  was	  shown	  that	  NKT	  cell	  deficient	  mice	  are	  more	  susceptible	  to	  influenza	  and	  that	  NKT	  cells	  are	  crucial	   to	   convert	   a	   Gr-­‐1+CD11b+	   population	   from	   a	   suppressive	   to	   a	   pro-­‐inflammatory	   profile	   [91].	   This	   population,	   often	   termed	   myeloid-­‐derived-­‐suppressor	   cells	   (MDSCs)	   comprises	   cells	   of	   both	   monocyte	   and	   neutrophil	  phenotype,	  and	  it	  will	  be	  interesting	  to	  determine	  the	  exact	  identity	  of	  the	  cells	  involved	   and	   the	   regulatory	  mechanism(s)	   at	  work.	   In	   a	  more	   recent	   study	  on	  the	  immune	  response	  to	  melanoma,	  the	  same	  group	  shows	  immunosuppressive	  effects	   mediated	   by	   IL-­‐10	   that	   is	   induced	   in	   neutrophils	   by	   serum	   amyloid	   A.	  This	  regulatory	  neutrophil	  profile	  is	  turned	  into	  a	  pro-­‐inflammatory	  one	  by	  CD1-­‐dependent	  interaction	  between	  NKT	  cells	  and	  neutrophils	  [92],	  thus	  suggesting	  a	  mechanism	  also	  for	  the	  observations	  made	  in	  influenza	  infection.	  	  Another	   important	  cytokine	  with	   immunoregulaory	   function	   is	  TGFβ.	  Tinoco	  et	  al.	  [93]	  compared	  LCMV	  strains	  causing	  acute	  or	  chronic	  infection	  and	  show	  that	  TGFβ	  induced	  SMAD2	  phosphorylation	  is	  enhanced	  in	  virus-­‐specific	  CD8+	  T	  cells	  early	  in	  chronic	  infection	  and	  that	  TGFβ	  contributes	  to	  CD8	  cell	  apoptosis.	  They	  also	   demonstrate	   that	   in	   a	   mouse	   model	   with	   selectively	   attenuated	   TGFβ	  
signalling	   in	  T	   cells	   [94],	   virus	   clearance	   is	   improved,	  mainly	   due	   to	   increased	  specific	  CD8+	  T	  cell	  responses.	  The	  authors	  find	  increased	  TGFβ	  in	  CD8+	  T	  cells	  in	   chronic	   infection	   and	   therefore	   propose	   an	   autocrine	   loop	   as	   a	   likely	  mechanism	  of	  CD8	  cell	  attenuation.	  However,	  the	  profound	  regulatory	  effects	  of	  TGFβ	  which	  mediate	  global	  effects	  on	  immune	  homeostasis	  [94]	  may	  hinder	  in-­‐depth	  analysis	  of	  the	  role	  of	  TGFβ	  in	  regulating	  immune	  responses	  to	  acute	  and	  chronic	  viral	  infections.	  	  
IL-­17	  and	  other	  Th17-­related	  cytokines	  The	  role	  of	  IL-­‐17	  has	  been	  extensively	  studied	  in	  bacterial	  infection,	  but	  less	  so	  in	  viral	   infection	   [87].	   As	   described	   above,	   IL-­‐10	   deficient	  mice	   develop	   a	   strong	  protective	  Th17	  response	  to	  influenza	  virus	  infection,	  but	  the	  same	  study	  shows	  that	  factors	  other	  than	  IL-­‐17	  itself	  mediate	  this	  protective	  effect.	  It	  could	  be	  that	  the	   production	   of	   IL-­‐22	   by	   Th17	   cells	   has	   a	   role	   in	   protection,	   as	   discussed	  below.	   IL-­‐17	   producing	   CD8	   T	   cells	   (Tc17)	   were	   shown	   to	   arise	   in	   influenza	  infection	  and	  to	  contribute	  to	  protection	  [95].	  Treatment	  with	  IL-­‐17	  neutralizing	  mAbs	   reduced	   protection	   from	   challenge	  with	   a	   heterologous	   influenza	   strain,	  suggesting	   a	   direct	   role	   for	   this	   cytokine,	   however,	   it	   is	   possible	   that	   in	   this	  scenario,	   IL-­‐22	   levels	   were	   also	   diminished.	   Similarly,	   in	  models	   of	   sequential	  infection	   by	   influenza	   and	   bacteria,	   increased	   susceptibility	   to	   bacteria,	   post	  influenza	  infection,	  was	  linked	  to	  impaired	  Th17	  responses	  [96].	  	  IL-­‐22	   is	   a	   cytokine	   associated	   with	   Th17	   responses	   and	   has	   been	   studied	  predominantly	   in	   bacterial	   infections	   in	   the	   lung	   [97]	   and	   the	   gut	   where	   it	  promotes	  epithelial	   integrity.	  A	  tissue-­‐protective	  role	  was	  shown	  for	   IL-­‐22	  also	  in	  liver	  injury	  [98,99]	  and	  in	  skin	  inflammation	  [100].	  Whether	  or	  not	  it	  also	  has	  a	  role	  in	  viral	  infections	  is	  less	  clear.	  It	  was	  shown	  that	  lung	  NK	  cells	  produce	  IL-­‐22	  in	  response	  to	  influenza	  infection,	  but	  no	  significant	  protective	  role	  was	  found	  [101].	  Intriguingly,	  treatment	  with	  IL-­‐22	  neutralizing	  Ab	  increased	  virus	  titers	  in	  this	  study.	  	  An	  interesting	  link	  between	  IL-­‐22	  and	  IL-­‐7	  was	  recently	  described	  in	  a	  model	  of	  therapeutic	   IL-­‐7	   treatment	   for	   chronic	   LCMV	   infection.	   IL-­‐7	   has	   been	   shown	  
previously	  to	  be	  a	  promising	  adjuvant	  for	  anti-­‐tumor	  vaccination	  [102].	  A	  more	  recent	  study	  demonstrates	  that	  IL-­‐7	  addition	  induces	  naïve	  and	  antigen-­‐specific	  T	   cells	   and	   increases	   the	   production	   of	   proinflammatory	   cytokines,	   whilst	  resulting	   in	   downregulation	   of	   TGFβ.	   The	   protective	   effects	   of	   IL-­‐7	   are	   IL-­‐6	  dependent	   and	   require	   the	   downregulation	   of	   the	   cytokine	   repressor	   SOCS3	  [103].	  The	  resulting	  enhancement	  of	  the	  immune	  response	  leads	  to	  accelerated	  LCMV	   clearance,	   and	   concomitant	   immune-­‐mediated	   liver	   pathology	   is	  prevented	   by	   increased	   IL-­‐22	   production.	   IL-­‐22	   blockade	   resulted	   in	   high	  aspartate	   transaminase	   (AST)	   levels	   indicating	   increased	   liver	   damage	   [103].	  While	  this	  study	  uses	  exogenous	  IL-­‐7	  for	  therapeutic	  purposes,	  it	  also	  raises	  the	  question	  whether	   IL-­‐7	   is	   produced	   endogenously	   in	   response	   to	   infection	   and	  whether	  it	  contributes	  to	  protection.	  It	  was	  shown	  that	  systemic	  TLR	  treatment	  induced	   IL-­‐7	   production	   by	   hepatocytes	   [104],	   and	   that	   this	   effect	   was	  dependent	   on	   IFNαβ	   signalling	   but	   not	   direct	   TLR	   signalling	   in	   hepatocytes.	  Collectively,	   these	   results	   suggested	   that	   TLR-­‐expressing	   cells	   are	   induced	   to	  produce	  IFNαβ	  which	  then	  acts	  on	  hepatocytes	  to	  induce	  IL-­‐7	  [104].	  Since	  viral	  infections	   invariably	   induce	   IFNαβ	   production	   and	   pathogens	   provide	   TLR	  agonists,	  these	  findings	  suggest	  that	  IL-­‐7	  may	  also	  be	  induced	  by	  viral	  infection.	  	  	  IL-­‐21	  is	  a	  cytokine	  associated	  with	  Th22	  (IL-­‐22	  producing	  T	  cells	  which	  do	  not	  produce	  IL-­‐17)	  and	  T	  Follicular	  Helper	  (TFH)	  cell-­‐responses.	  A	  series	  of	  papers	  have	   shown	   that	   CD4-­‐produced	   IL-­‐21	   is	   crucial	   to	  maintain	   Ag-­‐specific	   CD8	   T	  cells	   and	   protect	   them	   from	   exhaustion,	   allowing	   control	   of	   chronic	   LCMV	  infection	  [105-­‐107].	  In	  HIV	  patients,	  CD4	  T	  cell	  counts	  correlate	  with	  IL-­‐21	  levels	  [108,109].	  More	   recently,	   a	   requirement	   for	   IL-­‐21	   to	  maintain	  CD8	  T	   cells	  was	  also	   reported	   for	   acute	   LCMV	   infection	   [110],	   albeit	   with	   a	   less	   stringent	   role	  than	  in	  the	  chronic	  situation.	  	  	  
Th1	  cells	  and	  Th1-­related	  cytokines	  
	  Type	   II	   IFN	  or	   IFNγ	   binds	   to	   its	   distinct	   heterodimeric	   receptor	   formed	  by	   the	  two	   chains	   IFNγR1	   and	   IFNγR2	   that	   signal	   through	   Jak1	   and	   Jak2	   to	  
phosphorylate	   STAT1	   homodimers	   which	   then	   bind	   to	   IFN-­‐γ–activated	  sequences	  in	  the	  promoters	  of	  IFN-­‐γ–induced	  genes.	  IFN-­‐γ is	  produced	  by	  many	  cells	  of	  the	  innate	  and	  adaptive	  immune	  response	  including	  NK	  cells,	  CD4+	  and	  CD8+	  T	  cells,	  and	  has	  been	  suggested	  to	  play	  a	  role	   in	  the	   immune	  response	  to	  viral	   infection	   [12,13].	   A	   nonredundant	   role	   for	   IFNγ	   in	   controlling	   Theiler's	  virus,	  LCMV	  and	  vaccinia	  virus	  has	  been	  established	   [12,13].	  However,	   in	  most	  viral	   infections,	   an	   unequivocal	   protective	   role	   for	   IFN-­‐γ,	   as	   shown	   for	  mycobacterial	  infections	  in	  both	  mouse	  and	  man	  [111],	  was	  not	  found.	  This	  lack	  of	  requirement	  for	  IFNγ	  for	  protection	  against	  most	  acute	  viral	  infections,	  could	  be	   due	   to	   compensation	   by	   other	   IFNs	   through	   STAT1	   signalling	   pathways	   as	  suggested	  earlier,	  or	  because	  IFN-­‐γ	  activates	  anti-­‐viral	  immunity,	  by	  activation	  of	  dendritic	  cells	  to	  present	  antigen	  and	  activation	  of	  cytotoxic	  CD8+	  T	  cells	  [112],	  via	  pathways	  compensated	  by	  other	  cytokines.	  	  	  It	   has	   been	   demonstrated	   however,	   that	   low-­‐affinity	   cytotoxic	   T-­‐lymphocytes	  require	  IFN-­‐gamma	  to	  clear	  an	  acute	  viral	  infection	  [113].	  IFN-­‐γ	  production	  may	  play	  a	  simultaneous	  role	   in	  virus	  elimination	  and	   in	   inhibiting	  pathogenic	  Th2-­‐type	  responses.	  This	   is	  well	   illustrated	  by	  studies	  of	  RSV	  infection	  (reviewed	  in	  [114]).	   NK	   cells	   are	   transiently	   present	   in	   the	   early	   stages	   of	   RSV	   infection	   of	  mice	  and	  are	  a	  major	  source	  of	  IFNγ at	  day	  4,	  when	  cells	  of	  the	  acquired	  immune	  system	  start	  to	  accumulate	  in	  the	  lung.	  Whereas	  CD8	  T	  cells	  can	  cause	  enhanced	  weight	   loss,	   IL-­‐12-­‐	   activated	  NK	   cells	   inhibit	   lung	   eosinophilia	  without	   causing	  enhanced	  illness.	  However,	  depletion	  of	  both	  NK	  and	  CD8	  T	  cells	  allows	  RSV	  to	  spread	   to	  mediastinal	   lymph	  nodes,	   showing	   that	   either	   subset	   alone	   can	  have	  antiviral	  effects,	  presumably	  to	  a	  large	  extent	  by	  their	  production	  of	  IFNγ [115].	  Although	  primary	  RSV	  infection	  is	  normally	  dominated	  by	  IFNγ	  rather	  than	  Th2	  cytokines,	   severe	   bronchiolitis	   may	   be	   accompanied	   by	   evidence	   of	   Th2	  activation	   [116].	   However,	   compared	   to	   the	   case	   for	   other	   severe	   respiratory	  viral	  infections	  leading	  to	  lower	  respiratory	  tract	  infections,	  IFN-­‐γ	  production	  by	  peripheral	   blood	   mononuclear	   cells	   appears	   to	   be	   decreased	   in	   RSV	   disease,	  perhaps	  pointing	  to	  its	  role	  in	  pathogenesis	  [114].	  STAT1	  activation	  by	  both	  type	  I	   and	   type	   II	   IFNs	   has	   been	   shown	   to	   play	   an	   important	   role	   in	   establishing	   a	  
protective,	  Th1	  Ag-­‐specific	  immune	  response	  to	  RSV	  infection,	  however,	  with	  an	  accompanying	  preferential	  IL-­‐4,	  IL-­‐5,	  and	  IL-­‐13	  induction	  [117].	  	  
Th2-­	  and	  Th2-­	  related	  cytokines	  contribute	  to	  pathology	  in	  viral	  
responses	  	  RSV	  is	  a	  major	  clinical	  problem	  causing	  yearly	  epidemics	  of	  severe	  lower	  airway	  disease	   in	   both	   infants	   and	   the	   elderly.	   Attempts	   at	   vaccination	   have	   been	  frustrated	   by	   both	   the	   poor	   immunogenicity	   of	   this	   virus,	   and	   the	   severe	  immunopathology	   observed	   in	   early	   vaccine	   trials.	   Primary	   infection	   generally	  occurs	   in	   infancy,	   with	   approximately	   5%	   of	   infected	   infants	   requiring	  hospitalization	  with	  an	  apparent	  link	  between	  severe	  RSV	  disease	  and	  the	  later	  development	  of	  allergy	  and	  asthma	  [114].	  While	  there	  is	  no	  evidence	  that	  natural	  infection	   promotes	   Th2	   predominance,	   development	   of	   enhanced	   eosinophilic	  disease	   in	   children	   receiving	   inactivated	   virus	   administered	   with	   a	   commonly	  used	  adjuvant	  demonstrated	  how	  easily	  the	  balance	  between	  immune-­‐mediated	  protection	   and	   immune-­‐mediated	   pathology	   can	   be	   perturbed	   (reviewed	   in	  [114]).	  During	  RSV	  infection	  some	  T	  cells	  enhance	  disease,	  while	  others	  control	  it.	   	   In	   mice,	   primary	   signs	   of	   disease	   are	   reduced	   by	   CD4	   and/or	   CD8	   T-­‐cell	  depletion.	  Depletion	  of	   CD4+	  T	   cells	   or	   transfer	   of	   CD8+	  T	   cells	  modulates	   the	  eosinophilia	  seen	  in	  rVaccinia	  Virus-­‐RSV-­‐G-­‐protein	  (RSV-­‐G)	  primed	  RSV-­‐infected	  mice,	  while	  eosinophilia	  can	  be	  made	  to	  appear	   in	  strains	  that	  normally	  do	  not	  develop	  it,	  if	  CD8	  T	  cells	  are	  depleted	  or	  impaired	  in	  function.	  This	  suggests	  that	  Th2	  cells	  promote	  RSV-­‐induced	  eosinophilia	  and	  that	  CD8	  cells	  generally	  inhibit	  it.	   As	   described	   above,	   RSV	   G-­‐induced	   pathology	   is	   caused	   mainly	   by	   the	  overactive	  Th2	  CD4+	  T	  cells.	  Thus,	   the	  effects	  of	  RSV	  are	  mediated	  through	  the	  cytokines	  and	  chemokines	   that	   it	   induces,	  and	   these	  mediators	  will	  necessarily	  affect	  the	  outcome	  of	  an	  infection.	  The	  immune	  background	  of	  the	  neonatal	  lung	  is	   different	   from	   that	   of	   the	   adult	   lung	   with	   a	   general	   bias	   towards	   Th2	  responses.	   For	   example,	   CD4+	  T	   cells	   show	  hypermethylation	   in	   the	   promoter	  region	   of	   the	   IFN-­‐γ	   gene,	   affecting	   transcription	   efficiency,	   and	   IL-­‐12	   gene	  transcription	   is	   reduced	   in	   neonatal	   human	   monocyte-­‐derived	   dendritic	   cells	  (reviewed	   in	   [114]).	   It	  may	  be	   that	   these	   factors	   in	   part	   account	   for	   enhanced	  
disease	  severity	  in	  RSV-­‐infected	  infants.	  	  Formaldehyde	   is	  widely	  used	   in	  making	  vaccines	  but	  has	  been	  associated	  with	  atypical	   enhanced	   disease	   during	   subsequent	   infection	   with	   paramyxoviruses	  [114].	   Openshaw	   et	   al.	   have	   shown	   that	   carbonyl	   groups	   on	   formaldehyde-­‐treated	  vaccine	  antigens	  boost	  Th2	  responses	  and	  enhance	  RSV	  disease	  in	  mice,	  an	   effect	   partially	   reversible	   by	   chemical	   reduction	   of	   carbonyl	   groups.	   Innate	  sensing	   of	   damaged	   proteins	   may	   thus	   profoundly	   affect	   immunogenicity,	  changing	   the	   balance	   between	   protective	   and	   deleterious	   immune	   responses	  [118].	  	  
IL-­9	  in	  anti-­viral	  responses	  	  IL-­‐9	   is	   a	   cytokine	   of	   great	   current	   interest	   associated	   with	   allergic/Th2	  responses.	   	  High	   levels	  of	   IL-­‐9	  are	  present	   in	  bronchial	   secretions	   from	   infants	  with	   RSV	   bronchiolitis.	   	   Recently,	   it	   has	   been	   shown	   that	   IL-­‐9	   depletion	   in	   a	  vaccine	  sensitization	  mouse	  model	  enhanced	  RSV	  clearance	  regardless	  of	  timing,	  but	  caused	  remarkably	  different	  effects	  on	  the	  immunopathogenesis	  of	  disease	  at	  different	  phases	  of	  the	  response.	  Depletion	  only	  at	  the	  time	  of	  RSV	  challenge	  had	  little	   effect	   on	   disease	   severity,	   but	   depletion	   at	   both	   immunization	   and	  challenge	   enhanced	   disease,	   increased	   lymphocytosis	   and	   enhances	   IFN-­‐γ	   and	  TNF	   secretion	   by	   CD4	   T	   cells	   while	   abrogating	   Th2	   cytokine	   production.	  Paradoxically,	   IL-­‐9	   depletion	   at	   the	   time	   of	   immunization	   alone	   alleviated	  disease	  by	  reducing	  subsequent	  Th2	  cytokine	  production	  without	  a	  concomitant	  increase	  in	  IFN-­‐γ	  or	  TNF	  production	  [119].	  This	  complex	  situation	  illustrates	  the	  difficulty	   of	   using	   immune	   manipulation	   to	   modulate	   acute	   virus-­‐induced	  disease,	  since	  effects	  of	  immune	  interventions	  may	  be	  critically	  dependent	  on	  the	  stage	  of	  immune	  priming	  or	  recall.	  	  
Outlook	  	  We	   are	   coming	   closer	   to	   understanding	   the	   complex	   cytokine	   interactions	   in	  immune	   responses	   to	   infection.	   This	   knowledge	   will	   enable	   us	   to	   distinguish	  
microbe-­‐induced	   damage	   from	   immunopathology	   and	   to	   identify	   the	  mechanisms	   at	   work,	   with	   the	   prospect	   of	   intervention	   to	   boost,	   direct	   or	  dampen	  immune	  responses	  as	  necessary.	  However,	  numerous	  examples	  cited	  in	  this	  review	  show	  how	  relatively	  small	  differences	  in	  pathogen	  load	  or	  strain,	  in	  host	  genetic	  background	  and	  in	  timing	  and	  scale	  of	  immune	  intervention	  change	  the	   outcome	   dramatically,	   particularly	   in	   acute	   viral	   responses.	   Therefore,	   the	  increasing	  complexity	  of	  the	  accumulating	  data	  should	  also	  teach	  us	  a	  lesson	  in	  humility	  when	  we	  attempt	  to	  move	  from	  our	  relatively	  well-­‐controlled	  models	  of	  single	   infections	   of	   clean	   animals	   out	   to	   the	   dirty	   roads	   of	   human	   infectious	  disease.	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